About Insmed (NASDAQ:INSM)
Insmed Incorporated is a biopharmaceutical company. The Company operates through development and commercialization of therapies for patients with rare diseases segment. Its lead product candidate is ARIKAYCE, or liposomal amikacin for inhalation (LAI), which is in late-stage development for adult patients with treatment refractory nontuberculous mycobacteria (NTM) lung disease caused by Mycobacterium avium complex (MAC). Its earlier-stage pipeline includes preclinical compounds that the Company is evaluating in multiple rare diseases of unmet medical need, including methicillin-resistant staph aureus and NTM. Its earlier clinical-stage pipeline includes INS1007 and INS1009. INS1007 is an oral, reversible inhibitor of dipeptidyl peptidase 1. INS1009 is an inhaled nanoparticle formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. It has completed a Phase I study of INS1009.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Bio Therapeutic Drugs
- Sub-Industry: N/A
- Symbol: NASDAQ:INSM
- CUSIP: N/A
- Web: www.insmed.com
- Market Cap: $1.67 billion
- Outstanding Shares: 62,377,000
- 50 Day Moving Avg: $29.13
- 200 Day Moving Avg: $19.38
- 52 Week Range: $10.21 - $31.84
Sales & Book Value:
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.75
- P/E Growth: 0.00
- Annual Revenue: N/A
- Price / Sales: N/A
- Book Value: $1.34 per share
- Price / Book: 19.99
- EBITDA: ($180,870,000.00)
- Return on Equity: -130.41%
- Return on Assets: -85.48%
- Debt-to-Equity Ratio: 0.66%
- Current Ratio: 3.67%
- Quick Ratio: 3.67%
- Average Volume: 1.45 million shs.
- Beta: 0.93
- Short Ratio: 5.54
Frequently Asked Questions for Insmed (NASDAQ:INSM)
What is Insmed's stock symbol?
Insmed trades on the NASDAQ under the ticker symbol "INSM."
How were Insmed's earnings last quarter?
Insmed, Inc. (NASDAQ:INSM) released its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.72) EPS for the quarter, missing the Zacks' consensus estimate of ($0.63) by $0.09. View Insmed's Earnings History.
When will Insmed make its next earnings announcement?
Where is Insmed's stock going? Where will Insmed's stock price be in 2017?
7 analysts have issued 1 year price objectives for Insmed's stock. Their predictions range from $17.00 to $54.00. On average, they expect Insmed's stock price to reach $36.71 in the next twelve months. View Analyst Ratings for Insmed.
Who are some of Insmed's key competitors?
Some companies that are related to Insmed include Sarepta Therapeutics (SRPT), BeiGene (BGNE), Agios Pharmaceuticals (AGIO), AveXis (AVXS), GW Pharmaceuticals PLC (GWPH), Spark Therapeutics (ONCE), Loxo Oncology (LOXO), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Prothena Corporation PLC (PRTA), China Biologic Products (CBPO), Ultragenyx Pharmaceutical (RARE), Array BioPharma (ARRY), Intercept Pharmaceuticals (ICPT), NovoCure Limited (NVCR), Radius Health (RDUS), Acceleron Pharma (XLRN) and AnaptysBio (ANAB).
Who are Insmed's key executives?
Insmed's management team includes the folowing people:
- William H. Lewis, President, Chief Executive Officer, Director
- Paolo Tombesi, Chief Financial Officer
- S. Nicole Schaeffer, Senior Vice President- Human Resource and Corporate Services
- Walter Perkins Ph.D., Chief Technology Officer
- Eugene Jeffrey Sullivan M.D., Chief Product Strategy Officer and Chief Scientific Officer
- Mark Quigley, Vice President- Quality Assurance
- Christine A. Pellizzari, General Counsel, Corporate Secretary
- Roger Adsett, Chief Commercial Officer
- Paul Streck, Chief Medical Officer
- Donald J. Hayden Jr., Non-Executive Chairman of the Board
Who owns Insmed stock?
Insmed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Nationwide Fund Advisors (0.07%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter, Orlov S Nicole Schaeffer and William Lewis. View Institutional Ownership Trends for Insmed.
Who bought Insmed stock? Who is buying Insmed stock?
Insmed's stock was purchased by a variety of institutional investors in the last quarter, including Nationwide Fund Advisors. Company insiders that have bought Insmed stock in the last two years include Christine A Pellizzari and William Lewis. View Insider Buying and Selling for Insmed.
How do I buy Insmed stock?
Shares of Insmed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Insmed's stock price today?
MarketBeat Community Rating for Insmed (NASDAQ INSM)MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Insmed stock can currently be purchased for approximately $26.78.
Consensus Ratings for Insmed (NASDAQ:INSM) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 6 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.86)|
|Consensus Price Target: ||$36.71 (37.10% upside)|Consensus Price Target History for Insmed (NASDAQ:INSM)
Analysts' Ratings History for Insmed (NASDAQ:INSM)
(Data available from 10/24/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/6/2017||Cowen and Company||Reiterated Rating||Outperform||$54.00||High|
|9/6/2017||Stifel Nicolaus||Reiterated Rating||Buy||$27.00 -> $43.00||High|
|9/6/2017||Robert W. Baird||Reiterated Rating||Outperform -> Positive||$23.00 -> $32.00||High|
|9/6/2017||HC Wainwright||Reiterated Rating||Buy||$35.00||High|
|9/5/2017||Leerink Swann||Boost Price Target||Outperform||$27.00 -> $36.00||High|
|9/5/2017||Evercore ISI||Boost Price Target||Outperform -> Outperform||$28.00 -> $40.00||High|
|6/11/2017||Citigroup Inc.||Reiterated Rating||Neutral||$14.00 -> $17.00||High|
|8/21/2016||Piper Jaffray Companies||Set Price Target||Buy||$24.00||N/A|
Earnings History for Insmed (NASDAQ:INSM)Earnings History by Quarter for Insmed (NASDAQ INSM)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/3/2017||Q1 2017||($0.60)||($0.60)||$0.30 million||View||Listen|
|8/6/2013||Q2 2013||($0.32)||($0.28)||$5.38 million||View||Listen|
Earnings Estimates for Insmed (NASDAQ:INSM)
2017 EPS Consensus Estimate: ($2.40)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Insmed (NASDAQ:INSM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Insmed (NASDAQ:INSM)
Insider Ownership Percentage: 4.03%Insider Trades by Quarter for Insmed (NASDAQ:INSM)
Institutional Ownership Percentage: 73.08%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/7/2017||Donald J Hayden Jr||Director||Sell||45,000||$29.67||$1,335,150.00|| |
|9/6/2017||Melvin Md Sharoky||Director||Sell||50,000||$27.37||$1,368,500.00|| |
|5/31/2017||Christine A Pellizzari||General Counsel||Buy||10,000||$15.14||$151,400.00|| |
|12/15/2016||Christine A Pellizzari||General Counsel||Buy||20,000||$12.81||$256,200.00|| |
|12/14/2016||Myrtle S Potter||Director||Sell||6,466||$12.79||$82,700.14|| |
|11/14/2016||Andrew T Drechsler||CFO||Sell||45,000||$14.67||$660,150.00|| |
|11/9/2016||Orlov S Nicole Schaeffer||SVP||Sell||68,774||$11.95||$821,849.30|| |
|2/1/2016||William Lewis||CEO||Buy||50,000||$13.34||$667,000.00|| |
|9/2/2015||Donald J. Hayden, Jr.||Director||Sell||25,000||$24.06||$601,500.00|| |
|5/12/2015||Mark Quigley||VP||Sell||18,750||$22.07||$413,812.50|| |
|8/13/2014||Melvin Md Sharoky||Director||Buy||88,889||$11.25||$1,000,001.25|| |
|11/1/2013||William Lewis||CEO||Buy||5,233||$14.28||$74,727.24|| |
|7/22/2013||Fmr Llc||Insider||Sell||158,758||$12.02||$1,908,271.16|| |
|7/18/2013||Fmr Llc||Insider||Sell||310,227||$11.49||$3,564,508.23|| |
|7/15/2013||Fmr Llc||Insider||Sell||161,531||$10.79||$1,742,919.49|| |
|7/9/2013||Fmr Llc||Insider||Sell||146,599||$10.01||$1,467,455.99|| |
|7/3/2013||Fmr Llc||Insider||Sell||365,779||$9.96||$3,643,158.84|| |
|7/1/2013||William Lewis||CEO||Buy||7,585||$9.83||$74,560.55|| |
|6/24/2013||Fmr Llc||Insider||Sell||50,000||$12.00||$600,000.00|| |
|6/20/2013||Fmr Llc||Insider||Sell||143,088||$12.24||$1,751,397.12|| |
|6/12/2013||Fmr Llc||Insider||Sell||85,758||$13.00||$1,114,854.00|| |
|6/6/2013||Fmr Llc||Insider||Sell||130,557||$12.85||$1,677,657.45|| |
|4/1/2013||William Lewis||CEO||Buy||9,816||$7.58||$74,405.28|| |
|1/9/2013||William Lewis||CEO||Buy||10,770||$6.90||$74,313.00|| |
|12/3/2012||William Lewis||CEO||Buy||13,568||$7.36||$99,860.48|| |
Headline Trends for Insmed (NASDAQ:INSM)
Latest Headlines for Insmed (NASDAQ:INSM)
Loading headlines, please wait.
Insmed (INSM) Chart for Tuesday, October, 24, 2017